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ABSTRACT
Point-of-care (POC) tests are a reliable, portable, easy to use, and more affordable
alternative to regular laboratory diagnostic tests. They bypass the necessity of expensive
equipment, human labor, and technical expertise. The personal glucose meter (PGM) is
a POC device that measures glucose levels in blood. Lately, the PGM have been used as
a tool to detect other bioanalytes in different applications. There are two analytes which
POC detection would be beneficial for patients: creatinine and tacrolimus. Creatinine is
used to calculate glomerular filtration rate, a measurement of kidneys function that can
help to diagnose kidney failure, and other nephropathies. Tacrolimus is an
immunosuppressant drug used after organ transplantation to avoid rejection.
Tacrolimus has a narrow therapeutic window, and keeping the right amount drug in
blood circulation is crucial for the treatment. Hence, the design of a POC technique to
detect such analytes, without the cost and difficulty factors of current detection
methods, is the priority of this research project. Two strategies to detect these
bioanalytes are being proposed.
First, an invertase-mediated strategy, which uses magnetic nanoparticles, is
described. It relies on a competitive immunoassay for which the competitor is an
invertase conjugate. The magnetic nanoparticles were functionalized with antibody
coated gold. Their particle size distribution was 20 nm approximately. Three
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approaches were tried in order to conjugate invertase to the analytes. An EDC-NHS
crosslinking of creatinine butanoic acid and invertase seems to be the most promising
technique. Nevertheless, the final immunoassays were not successful.
The second strategy was based in glucose-loaded mesoporous silica
nanoparticles (MSN) capped with antibody coated gold nanoparticles (AuNP-Ab). MSN
were prepared with a modification of the Stöber method, and then coated with
polyethylenimine. The AuNP-Ab were made following a modified version of the
Turkevich method. After characterization, both nanoparticles looked and behaved as
expected, PEI-MSN particle size was near the 200 nm, and AuNP-Ab size was around
16 nm. However, immunoassays did not succeed. An optimization of the ratio of
AuNP-Ab and MSN is suggested in order to reach the goal of bioanalyte detection
using glucose-loaded MSN.
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CHAPTER ONE:
INTRODUCTION
A physicians’ ability to give precise and accurate diagnostics has been improved
thanks to the analysis of patients’ biological molecules, known as bioanalyte. Physical
exams, although common, do not allow obtaining definitive diagnostic answers 1.
Unfortunately, most medical diagnostic tests require several hours of human labor, as
well as training sessions, and they are inherently expensive. Nonetheless, efforts are
shifting to pursue a different way to obtain the similar results with less resources, time
and human expertise 2,3.
Point-of-Care Biodetection
Medical tests that offer reliable results and require neither the trained personnel
for tedious and time intensive lab processing, nor the infrastructure and complex
equipment, are known as Point-of-Care (POC) biodiagnostics 2. POC has been mainly
useful for routine assays that are needed on a regular basis for the same patient, and
assays that are conducted continuously in clinics, and hospitals. Yet, POC test have
gained relevance in chronic disease prevention and control, where time is crucial and
patients need more resources 2,4.
POC tests are involved in a wide variety of diseases, conditions, and routines;
thus, the diversity of technological diversity associated with them is not surprising. The
1

technology implemented depends on different factors and each has its own strengths
and weaknesses. Hence, to determine which one is most appropriate requires
experimentation 4,5. One of the most popular branches of POC devices involved lateral
flow assay (LFA). In these tests, a sample is analyzed at the same time that it is
transferred by capillarity from one extreme of a paper to the other one. These tests have
been around for roughly three decades. However, even though inexpensive, they still
are in the early stages of development, with significant room for improvement 6. The
main applications where paper-based POC has successfully reveal qualitative results
are pregnancy test or HIV infection; however their main limitation is the impossibility
of generating quantitative results 3.
Other examples of POC devices are electrochemical devices, which read an
electric signal that is produced by a chemical reaction. These devices could use
amperometers, potentiometers, all depending on the reaction involved 7. The amount of
scientific publications on the topic has been increasing exponentially the last ten years.
Unlike paper based POC, electrochemical POC offer more accurate results, more
sensitivity, stability, response time and specificity. Counterintuitively, electrochemical
devices are low cost and very portable. Unfortunately, some of them can have short
usage life, and poor chemical stability, but hopefully promising enhancements may be
accessible in the near future 8.
Personal Glucose Meter
Perhaps the most popular device created so far for POC testing, is the personal
glucose meter (PGM). This pocket-size, low cost device offers quantitative, trusty results
2

9,10.

It is available in stores and it has helped save countless lives of people with

diabetes, especially type 1 diabetes 11. Initially, the PGM was designed to be a tool to
help monitor the approximate concentration of glucose in blood. Usually, the detector is
either an electrode that measures electrons from the conversion of glucose into gluconic
acid or a sensor that measures changes in color in a colorimetric reaction 11. However,
even though these devices are only able to measure glucose, different researchers have
used a PGM to detect other molecules by indirect generation of glucose or a redox agent
involved in the enzymatic reactions in the PGM 9,12-16. These approaches of using PGM
as a versatile instrument bypasses years of research and money needed to create a new
device every time a new molecule needs to be detected. It also maximizes the health
centers and patients’ capabilities to monitor all of their detection needs in only one
device 15.
The role of nanotechnology in POC tests
Nanoparticles (NPs) offer features especially useful for POC devices, which are
thought to be small, easy to use and inexpensive. According to the distinct properties of
NPs, some of them are more prevalent in different niches of POC devices. For example,
due to their optical properties, quantum dots (QDs), carbon NPs, gold NPs, and other
unconventional NPs, are being used with smartphones, CDs, DVDs, scanners, or a strip
reader to obtain results through an optical readout 4. Physical properties, such as
functioning as carries, are also useful for the development of new devices. Silicone NPs,
polymers, silica NPs and gold NPs are commonly used as a carrier material for
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electrochemical devices, such as the PGM 4. Magnetic NPs are commonly used in POC
techniques for separation steps after a molecule adheres to or separates from them 9,16
Gold NPs are particularly useful because of their vast diversity; their properties change
with shape variation and they can be made in the shapes of spheres, rods, hollow
spheres, rings, and others. Gold NPs are known to change their color after aggregation,
are easy to functionalize with biomolecules, have good stability and are good at
enhancing results according to their geometry 17. In electrochemical tests, gold NPs offer
good conductivity and catalytic activity, as well as magnificent surface area to volume
ratio. Plus, they serve as a carrier for other molecules necessary in the application 16,17,
such as antibodies 17.
Magnetic NPs are also useful in this field, even though they are not as common
as gold NPs in POC diagnostics. Usually, magnetic NPs are used for separation
purposes where undesired reagents or substances are removed from the solution 9,17,18.
Such task is accomplished either by coating the magnetic NPs with a primary antibody,
making the magnetic NP directly proportional to the desired result, 16 or binding
trapped enzymes to the magnetic beads and pulling them out once the enzymes has
been released from them 9.
Because of their inert characteristics, silica nanoparticles are often used in POC
testing methods too. For example, carboxylic functionalized silica nanoparticles have
been used to improve detection of HIV down to the femtogram range. The silica beads
are attached to biotin, and enhance the detection capabilities of the equipment that
reads the plate 19. Silica has also been used in paper-based LFA to improve the
4

adsorption of some enzymes to the paper. This results in preserved discoloration of the
paper over time after the reactions occur 20. Sometimes, silica nanoparticles are chosen
because of their physical properties, such as their stability and size, which make them
good carriers for other species in biodiagnostic tests 4. For instance, silica NP also show
capabilities of improving the most common tests such as pregnancy tests and drug-ofabuse tests by loading them with a bright label. Europium chelate-loaded silica
nanoparticles can improve the lower limit of detection of common LFA tests down 100
times 21
Invertase-Mediated Detection
Invertase is a common reagent in the development of these new techniques to
detect molecules indirectly with the PGM 9,16,22. Invertase readily catalyzes sucrose into
glucose and fructose. Since the PGM does not read concentrations of fructose, catalyzed
sucrose is directly proportional to the glucose measured. However, it may not be
proportional to the concentration of the original analyte. Invertase can exponentially
increase the sensitivity of the PGM since one enzyme can cleave multiple sucrose
molecules. As a result, it is possible to obtain detectable readings from concentrations of
the target as low as picomolar into glucose concentration in the micromolar range 22.
Furthermore, some invertases, such as yeast invertase, are sturdy enzymes that can
tolerate a wide range of temperature and pH, while having a good substrate specificity
and high activity, thus facilitating POC applications with PGM 22.
Different approaches can be used to achieve a glucose concentration in
proportion to the target molecule’s concentration using invertase as the intermediary. In
5

2015, Zhao, et al. used graphene oxide – gold nanoparticles (NPs) as a platform to
immobilize a secondary antibody and also invertase. This platform recognized
molecules of albumin previously attached to a primary antibody in a technique
comparable to ELISA. Another team focused their efforts toward aptamers and
DNAzymes; different molecules such as cocaine, adenosine, and the interferon-gamma
of tuberculosis were targeted. In this case invertase was sequestered in DNA-invertase
conjugates attached to magnetic beads; in the presence of the targets, this DNA aptamer
changed its configuration thus releasing the enzyme from the magnetic bead and then
converting the sucrose into glucose after the extraction of the magnetic beads from the
solution 9. Metal ions and target DNA sequences could also be detected using a similar
technique 23,24. It is also possible to conjugate invertase to other molecules such as biotin
in order to develop a reveal mechanism based on streptavidin-biotin binding. In this
way biotinylated primary antibodies can recognize the target molecule, then
streptavidin will interact with that and finally biotin-invertase will be added to the
solution 25. Invertase can also be bound to a polymer chain that contains an antibody
anti target molecule, and many invertases in a single polymer. This ratio difference
between invertase and antibody results in a higher ability to amplify the result, making
it possible to detect even 5 ng of the desired analyte 26. These data show that invertase
may be an outstanding tool to reach the purpose of many PGM biodetection techniques.
Mesoporous Silica Nanoparticles (MSN) Mediated Detection
The synthesis of mesoscopic materials dates back to the 1970s. However, the first
MSN particle was synthetized in 1992 by Mobil Research and Development
6

Corporation. MSNs are considered a nanomaterial with an organized network of
channels of variable pore size (2-30 nm), which gives them a particularly large active
surface. Furthermore, particle size is a key feature for the biomedical application of
MSNs since it is critical for effective drug delivery 27. The classical synthesis method is a
cooperative self-assembly mechanism that consists of a polycondensation of an
inorganic precursor of SiO42- type around micelles of surfactants. It is organized in a
hexagonal network of cylindrical micelles around which the silica polymer will be
formed. The majority of the MSNs are fabricated by sol-gel process (also known as
Stober’s method). It implicates the hydrolysis and condensation of the alkoxide
monomers into a colloidal solution (sol), which turns as a precursor to form an ordered
network (gel) of discrete particles 28.
The high impact on MSN as drug carriers for the treatment of various diseases
has been proven. Overall, they are biocompatible, biodegradable and inert for the most
part which adds to its advantages. The release profile of drugs from MSNs chiefly
depends on its diffusion from the pores, which can be personalized by adjusting the
surface of the MSNs for certain biological needs 29. MSNs have been studied for a
variety of applications, and they have been successfully incorporated in anticancer
treatments 30, as well as an anti-inflammatory 31, antidepressant 32 or antihypertensive
treatments 33 among other biomedical applications.
Bioanalyte chosen
To recognize the target molecule in POC testing, different methods can be
pursued, such as DNA aptamers 9,23,24, molecularly imprinted polymers or MIP 34,
7

chemical reactions 26, or the most common tool: antibodies 4,16,25. Although expensive
compared with other options, antibodies have been known to be efficient at detecting
molecules for many years. They are fundamental to many detection methods, known as
immunoassays. According to how many antibodies recognize a molecule,
immunoassays can be separated in two main groups. Sandwich immunoassays need
two antibodies, one for molecule adhesion from the sample – primary antibody – and
another one, usually conjugated with an enzyme, for revealing purposes – secondary
antibody – which can either recognize the molecule or the combination primary
antibody/bioanalyte. Competitive immunoassays, in contrast, need only one antibody
to recognize the molecule in the sample. That same antibody can also recognize a
competitor molecule which is labeled to be detected, in a way where the final signaling
is inversely proportional to the target bioanalyte’s concentration 35. Each of them has
their own advantages. For example, the sandwich immunoassay is more specific, since
it recognizes the molecule twice, but hard to carry out with small molecules due to the
physical impediments of recognizing such molecules with two antibodies at a time.
Competitive immunoassays can be considered inexpensive since they use only one
antibody, and also fewer steps to get the response, but have higher chances of cross
reactivity inherent with some antibodies 35.
The molecules that can be recognized by antibodies, or any of the other
techniques, range from big molecules such as proteins, DNA, receptors, and viruses all
the way down to chemical compounds such as drugs, neurotransmitters, metabolites,
and others 36. Depending on the intention, choosing the bioanalyte is crucial because the
8

information that one analyte provides can be superior to another, or bioanalyte “A” can
be very specific for the problem while bioanalyte “B” can gives false positives. Under
these considerations, prior to development of a detection technique/device, research
must be done to determine the most adequate candidate analyte to be detected
according to the application. Another strategy is designing a diagnostic tool based on an
analyte that gives information that goes beyond one ailment. This project focuses on
two different molecules: creatinine and tacrolimus. Both are small molecules, known as
haptens, which are inherently difficult to detect as the literature shows 37-40.
Creatinine: Creatinine is a small molecule resulting from the metabolism of
creatine. It provides information about the state of the kidneys since they filter
creatinine from the blood. Creatinine levels in urine and serum can be used as monitors
for renal failure, diabetic nephropathy, glomerular filtration rate (GFR), and nephrotic
syndrome 1,41. It is periodically analyzed trough testing of blood or urine mainly
because it gives an insight of how concentrated the urine is, especially since variation in
fluid intake can alter concentration of substances in urine 42,43. Creatinine excretion
varies in humans across genders, but also correlates with the body’s muscular mass,
instead of the body’s weight 44, thus its concentration could be an index of change in
body’s muscular mass. Creatinine changes in urine can also occur as a consequence of
thyroid malfunction or muscular disorders 45. These features make creatinine a good
target for investigation.
Up to today, the technique to measure creatinine that is most commonly used
now was described in the 19th century and is based on the generation of creatinine9

picrate in a basic medium 46. However, this method is affected by many other
compounds in the sample, such as bilirubin, cephalosporin, aceto-acetates, glucose and
others. This colorimetric reaction technique is also altered by the picric acid
concentration, temperature, pH and wavelength 47. As a result of these interferences, the
“Jaffe method” usually overestimates creatinine with 15% to 25% range of error 47,48.
The use of picric acid has also been questioned, since it is such a volatile compound
comparable to other explosives such as TNT 1.
Creatinine can also be quantified by using FLA 49, capillary electrophoresis 50,51,
dynamic light scattering (DLS) 45, mass spectrometry 52, or HPLC 53-55, but none of these
techniques can be done without using expensive equipment and/or a trained
technician. Alternative methods and devices to detect creatinine have been explored;
enzyme-based tests modify the creatinine in the sample, generating a solution that can
be measured colorimetrically at the end of the reaction. When compared with the Jaffe
method, enzymatic reactions tend to be more expensive. They are also more specific for
creatinine and can detect lower levels 47. Immunoassays are an increasingly popular
option to measure creatinine also. Immunoassays can detect concentrations below the
human range of interest - limit of detection 4.5 ng/mL - and some of them are reusable
56.

Once again, the detection using standard immunoassays needs trained personal and

bulky equipment. Antibodies are coming to be replaced by MIPs as artificial receptors
or recognition sites. Such MIPs have also been used for the detection of creatinine 39.
Nanotechnology powered techniques have been developed too. For example, a
MIP with self-assembly capability made of iron oxide magnetic nanoparticles and
10

polyaniline was used to electrochemically determine creatinine in samples 57. Though
the technique is considerably cheaper, and could detect as little as 0.35 nmol/L 57, the
procedure is long and tedious and not suitable to be performed by a patient. Gold
nanoparticles (AuNPs) can help to determine the concentrations of creatinine based on
their plasmon surface properties. Label-free AuNPs can be used to trap creatinine, after
the molecule has been extracted from the urine sample using sulfonic acid
functionalized silica 58. This technique, although easy to perform, non-invasive, and
inexpensive, requires a previous cleaning of the sample, and the use of a
spectrophotometer. Other techniques are more promising. For example, a biosensor that
employs nanoparticles of creatininase, creatinase and sarcosine oxidase, original
enzymes from one of the most common methods of creatinine measurement, fixed on
an electrode 59. This biosensor is an amperometric device that lasts up to 240 days of
regular, multiple use without losing activity and is able to detect within 0.01 µM and 12
µM of creatinine after only two seconds 59.
POC techniques for creatinine measurement have emerged in the last decade 1.
Some of them are already on the market but they usually need a specific device with
different cartridges, strips or cassettes to function. These devices can work with samples
as small as 1 µL to those as large as 65 µL of whole blood. The time to obtain a response
varies from 30 seconds to almost 10 minutes 60. Most of the marketed devices are based
on enzymatic cascade reactions that finalize in a photometric or electrochemical
detection. The main drawback of such devices is the compulsory need of each
company’s instrument, generally a bench top machine that weighs at least 5 kg 60 and
11

inescapable increase of the price per test. An ideal POC device should be inexpensive,
portable and readily available especially if it is expected that consumers will use them
at home.
Tacrolimus: Tacrolimus is a macrolide molecule used as an immunosuppressive
drug to prevent organ rejection in patients after allogeneic organ transplants 61. The
therapeutic window of tacrolimus, also known as FK506, is narrow. High
concentrations of FK506 may induce nephrotoxicity, gastrointestinal tract
complications, and even neurotoxicity. The blood concentration of tacrolimus should be
kept between 5 and 20 ng/mL in order to obtain the best results 37,62. Therefore, the
need of closely monitoring the drug concentration in blood has arisen. There are
methods that can determine such concentration of tacrolimus in whole blood such as
ELISA methods and HPLC 61. However, neither of these alternatives fulfills the
requirement of continuously monitoring the drug in blood. The different ELISA
methods used to detect tacrolimus usually take over a day of processing before getting
results. In the HPLC case, even though it is more reliable and faster method, it requires
high cost due to the necessary instrumentation and the skilled technicians. As an
alternative to these procedures, a technique using nanoparticles, antibody/antigen
recognition, and the personal glucose meter could be beneficial for patients without
experience in biomolecules testing.
Although the literature in POC detection may look overwhelming, there are only
a few devices and techniques that have the potential to be developed further. One
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possibility that is being explored is the use of the PGM as a tool to indirectly determine
the concentration of biomolecules in human samples. If achieved, this technique will
minimize technicalities and costs, while improving availability and portability to
patients and caregiving professionals. Literature review reveals at least two basic
strategies for achieving this. For one, using invertase conjugated to the analyte of
interest in a competitive immunoassay with magnetic nanoparticles for easy sample
processing has the potential to be developed. Similarly, glucose loaded MSNs are
considered good candidates for POC diagnostics. These techniques may match the
quality and reliability of many of the products in the market, and exceed them in terms
of cost-benefit.
Objectives
Considering the above discussion, a method to detect both, creatinine and
tacrolimus through a POC device, would be beneficial for patients. Thus, two
approaches to reach this goal will be presented. The first one is based on the activity of
invertase and a competitive immunoassay that occurs on the surface of magnetic
nanoparticles. The second one is based on glucose-loaded MSN, capped with gold,
which release the glucose to the solution after interaction with the analyte. Either way,
the glucose produced will be measured using a PGM and then the glucose will correlate
to the concentration of the original analyte.

13

CHAPTER TWO:
MATERIALS AND METHODS
Invertase Mediated Strategy
PDDA-Au-IO-Ab nanoparticles synthesis: Poly(diallyldimethylammonium
chloride) (PDDA) (20 wt %), bovine serum albumin (BSA), Gold tetrachloride hydrate
(Chloroauric acid, HAuCl4), and Iron Oxide (II,III) nanoparticles (avg. size 25 nm) were
purchased from Sigma Aldrich. Unconjugated, mouse, monoclonal, anti-tacrolimus,
antibody (clone FK1) was purchased from GeneTex. Unconjugated, sheep, polyclonal,
anti-creatinine, antibody was purchased from Abcam. Nanopure water was used for all
the experiments; tubes and tips were autoclaved before use.
First, in a 150 mL glass Erlenmeyer flask, the PDDA protected gold nanoparticles
(PDDA-AuNP) were made. To do so, 40 mL of water with 250 µL of PDDA (4 wt %,
diluted in water) were stirred with magnetic stirrer with 200 µL of NaOH (0.5 M) and
100 µL of HAuCl4 (10 mg/mL dissolved in water), in that order. The solution under
stirring was immediately heated to boiling point, covering the flask with a clock glass to
avoid too much evaporation. Once at boiling point, the hot plate temperature was
diminished to reduce evaporation. After 20 minutes the hot plate was turned off, once
the solution had a red color (similar to wine). The solution was left to cool down at
room temperature, and later it was stored in the refrigerator (4 °C).
14

After those nanoparticles were prepared, the iron oxide was added to form
PDDA-Au-IONP. In a 2 mL micro-centrifuge tube a solution 1 mL of IO (5 mg/mL) was
mixed with 1 mL of PDDA-AuNP prepared earlier. The mixture was sonicated for 30
minutes. After that, the solution was left over a magnet for 40 minutes. The pellet with
the magnetic nanoparticles was kept, while the supernatant was discarded. This pellet
was washed two more times, using 1 mL of water every time. The final solution,
resuspended in 1 mL of deionized water, was stored at 4 °C.
Finally, these PDDA-Au-IONPs were coated with antibodies, specific to the
analyte of interest. First, the PDDA-Au-IONPs were washed from the water and
resuspended in 1 mL phosphate buffered saline, pH 7.4, (PBS buffer). After, 1 mL of
antibody anti-tacrolimus or anti-creatinine (Abtac, or Abcre 100µg/mL) was added to the
PDDA-Au-IONPs, in a 2 mL micro-centrifuge tube. The mixture was left mixing on a
moving platform at 4 °C overnight. The next morning, the PDDA-Au-IO-Ab-NPs were
washed by means of using a magnet for 30 minutes to pull down the magnetic
nanoparticles, and then replacing the supernatant with PBS. That procedure was
repeated three times. Finally it was resuspended in 1 mL of PBS with BSA (0.1 %), and
stored at 4 °C.
Invertase conjugation methods: Non conjugated invertase from Sacharomyces
cerevisie, creatinine, N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide (EDC), and NHydroxysuccinimide (NHS), was obtained from Sigma Aldrich. Tacrolimus was kindly
donated by Dr. Nirmal Sharma, as Prograf ® 5 mg, Astellas Pharma TG, Lot: 011518-07.
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Deionized water was used for all the experiments; tubes and tips were autoclaved
before use.
Invertase-Analyte shaking method: The procedure was carried out
following Barakat (2018), with some modifications. Briefly, 1 mL of invertase (20
mg/mL diluted in PBS), was mixed with 2 mL of tacrolimus (5 µg/mL diluted in PBS),
or 1 mL of creatinine (50 mg/mL diluted in PBS). The solution was shaken for four
hours at room temperature. After that the solution was stored at 4 °C, and used within
the next 24 hours.
EDC-NHS mediated Invertase-Creatinine conjugation method: The
protocol was adjusted from the original given by Sigma Aldrich. First, 20 mg of
invertase were diluted in 1 mL of PBS 10X. In a 5 mL round bottom flask, under an
argon atmosphere, the invertase dilution (1 mL) was stirring for 10 minutes when EDC
was injected (to create a final concentration of 0.142 mg/mL). After, NHS (to create a
final concentration of 0.57 mg/mL) was added to the solution. It was stirred for 30
minutes under the argon atmosphere. Then, creatinine in PBS buffer (pH 7.2) was
injected to the flask with a needle (final concentration 45 mg/mL). All of it was stirring
from the beginning of the experiment, until two and a half hours later, after all the
reagents were included. After that, the solution was washed in a dialysis tubing (30 kDa
cutoff) overnight, submerged in 500 mL of PBS. The dialysis buffer was changed three
times. The final product was then stored at 4°C until its use.
EDC-NHS mediated creatinine-butyric acid-Invertase conjugation
method: Dimethylformamide (DMF), potassium hydroxide, sodium hydroxide,
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hydrochloric acid, ethyl acetate, acetone, methanol, and ethanol were bought from
Sigma Aldrich. 4-bromobutyric aid ethyl ester was obtained from Alpha Aesar.
Creatinine butyric acid was synthesized following previous experiments 56.
2-imino-3-methyl-5-oxo-1-imidazolidinyl butyric acid ethyl
ester hydrobromide preparation: First 80 mmol of creatinine in 50 mL of DMF were
heated to 35 °C. After that the temperature was set to 85 °C and while heating, 100
mmol of 4-bromobutyric aid ethyl ester were added to the solution in drops (three per
minute). The solution was stirring during this process until the crystals of creatinine
dissolved completely (seven hours approximately). Then it was allowed to cool down
while stirring for three hours. Finally, the solution was added to 500 mL of ethyl acetate
and allowed to rest overnight for the crystal to precipitate. The next day, the crystals
were processed in a vacuum filtration and then, the crystals on the filter paper, were
washed with 200 mL of acetone, and filtrated again. The vacuum filtration system was
kept on for four hours to allow the crystals to dry.
2-imino-3-methyl-5-oxo-1-imidazolidinyl butyric acid ethyl
ester preparation: 2-imino-3-methyl-5-oxo-1-imidazolidinyl butyric acid ethyl ester
hydrobromide crystals were then neutralized with methanol (25 mL) and KOH (10
mmol). The solution was stirred for one hour at room temperature. After this, the
methanol was removed under reduced pressure overnight. The resulting crystals were
washed in ethanol. The resulting bromide salt precipitated and was filtered away. The
liquid solution that passed through the filter, was then put under reduced pressure to
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eliminate the ethanol, and obtain 2-imino-3-methyl-5-oxo-1-imidazolidinyl butyric acid
ethyl ester.
2-imino-3-methyl-5-oxo-1-imidazolidinyl butyric acid
preparation: The ester compound from above was then submitted to a hydrolysis
procedure. The ester was heated to 80 °C with NaOH (1.1 equivalent moles), in 25 mL of
water, for 5 hours under reflux. Later, the solution pH was decreased to 3 with
approximately 30 drops of pure concentrated HCL (12 M). Finally the acidic solution
was left under reduced pressure until obtaining an oily substance, the 2-imino-3methyl-5-oxo-1-imidazolidinyl butyric acid or creatinine butyric acid.
Thin layer chromatography: It was carried out in glass
plaques, with a mobile phase of methanol/chloroform in different ratios (1:9, 2:8, 3:7,
6:4). To compare, pure creatinine was one dot, and the new compound was another.
The EDC-NHS conjugation procedure was similar to the one described
above. The main difference was the starting point; in this case instead of invertase, it
was creatinine-butyric acid, which contained the carboxylic group. Briefly, under an
argon atmosphere, 10 mg/mL of creatinine butyric acid pH 6 (raised with NaOH), 0.4
mg of EDC, and 0.04 mg of NHS were stirred for 20 minutes. Then, 1 mL of invertase
(10 mg/mL, in PBS 10X buffer pH 7.3) was added to the solution and the reaction took
place overnight. Finally, the solution was dialyzed in a tubing with 3 kD cutoff for 12
hours, changing the dialysis buffer every two hours.
TNBS assay: 2,4,6-Trinitrobenzenesulfonic acid solution (TNBS, 5% w/v), and Llysine were purchased from Sigma Aldrich. The procedure was carried out following
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fabricant protocols. First, 500 µL of each sample (creatinine 90 mg/mL, invertase 10
mg/mL, and a calibration curve of L-lysine, from 100 mg/mL to 0.195 mg/mL in 1:2
serial dilutions) were prepared in sodium bicarbonate buffer (SBB, 0.1 M). Immediately
before the reaction, TNBS was diluted to 0.01% in SBB. In labeled microcentrifuge
tubes, 250 µL of TNBS were added to each sample (500 µL), they were mixed and
incubated for two hours in an incubator-shaker at 37 °C. After that, the reaction was
stopped with 250 µL of SDS (10%) and 125 µL of HCl (1 N). Finally, absorbance was
read at 335 nm.
Competitive immunoassay: Sucrose was purchased from Sigma Aldrich. A 96
well magnetic plaque was obtained to pull down the magnetic nanoparticles in 96 well
plates where the experiments were conducted. For each sample in every immunoassay
50 µL of PDDA-Au-IO-AbNP were verted in one well of the plate (done by duplicates).
Then, 50 µL of the sample or control were added to the well. The plate was shaken for
30 minutes to allow recognition of the analyte by the antibody. After that 50 µL of
invertase conjugate were added to the well and the plate was shaken again for 30
minutes, which permitted the competition of the invertase-analyte conjugate vs the
sample with the antibodies. Then, the plate was secured over the magnet for 30 minutes
until the magnetic nanoparticles were pulled to the bottom of the well. Next, the
supernatant was carefully removed with a pipette until the well was almost empty. The
well was then filled with 100 µL of PBS buffer to wash any unbound analyte or
invertase conjugate from the solution. The magnetic nanoparticles were pulled down
again, and the supernatant removed. Finally, 50 µL of sucrose (10 mg/mL) were added
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to the well, and the invertase reaction was allowed to occur for 20 minutes. Immediately
after, the PGM was used to read the amount of glucose in each well. Each experiment
had a negative control, where the magnetic nanoparticles were replaced by PBS,
meaning that any invertase would be left in the well after the washing step because
there was no magnetic nanoparticle to facilitate its retention. The positive control
contained no sample analyte, to prevent competition of the invertase conjugate for the
antibody. Instead, all the invertase conjugate would get trapped by the antibodies.
Before each experiment, every reactant: PBS buffer, sucrose, invertase conjugate,
magnetic nanoparticles, and samples were tested to rule out the presence of glucose
before the enzymatic reaction. The invertase activity was separately tested to make sure
that it was functioning before each assay. ELISA was conducted for each antibody (antitacrolimus and anti-creatinine) to make sure the antibodies were working.

Mesoporous Silica Nanoparticles Mediated Strategy:
AuNP-Ab synthesis: Sodium citrate, sodium phosphate monobasic, disodium
phosphate, sodium chloride, magnesium chloride and sodium carbonate were used
from Sigma Aldrich. PGM buffer (pH 7.3) was prepared as described by Tang, et al.,
(2014); it is compounded of disodium phosphate (72.9 mM), sodium phosphate
monobasic (27.1 mM), sodium chloride (50 mM), and magnesium chloride (5 mM) in
nanopure water.
Gold nanoparticle preparation: Gold nanoparticles were made using the
citrate reduction method, also known as the Turkevich method. To do so, 50 mL of
20

HAuCl4 (0.01% w/v) in a 100 mL Erlenmeyer flask, were stirred and heated to boiling
point. Once boiling, and maintaining the stirring, 2 mL of sodium citrate (1% w/v) were
rapidly added into the solution. After 10 minutes, once the color of the liquid changed
to red, the heat was turned off, and the flask was placed on ice, maintaining the stirring.
The solution was stirred for two more hours until the sample sufficiently cooled.
Afterward, the solution’s pH was adjusted to 9 with sodium carbonate and it was
stored at 4 °C.
Gold Antibody conjugation: 1 mL of the gold nanoparticles made before
were added to a microcentrifuge tube. Antibody anti morphine was added to the gold
to reach a final concentration of 100 µg/mL. After mixing, the colloid was stored at 4 °C
overnight to allow the antibodies attachment to the AuNP. The next morning, the
coated nanoparticles were centrifuged 30 minutes at 10 krcf (Eppendorf, model 5415D,
rotor F45-24-11). The supernatant was carefully removed with a pipette, and then
replaced with water to wash any non-bound antibody. The centrifugation step was
repeated and finally the nanoparticles were resuspended in 1 mL of PGM buffer with
BSA (1%).
PEI coated Mesoporous Silica Nanoparticles synthesis: Cetyl Trimethyl
Ammonium Bromide (CTAB), Polyethylenimine (PEI), and Tetraethyl orthosilicate
(TEOS), were obtained from Alpha Aesar.
MSN preparation: The method used was described in Théron, et al. (2014).
First, in a round bottom flask, with a magnetic stirrer on, 0.315 g of CTAB and 1.1 mL of
NaOH (2 M) in 150 mL of water, were heated to 80 °C for 30 minutes. The flask was
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capped with foil as much as possible at all times to reduce evaporation. Then, 1.4 mL of
TEOS were added dropwise to the solution at a rate of two drops per minute. The
solution was kept on heat for two hours and after it was centrifuged 10 minutes at 4.4
krcf (Eppendorf, model 5702, rotor A.8.47). The supernatant was discarded and all the
pellets were collected into two tubes. Then the resulting MSNs were vortexed in ethanol
and centrifuged again two more times. After that, the CTAB was extracted by heating to
60 °C under reflux the nanoparticles; they were in a solution of 160 mL of ethanol and 9
mL of concentrated HCL (12 M) in a round bottom flask with stirring. After, the
nanoparticles were centrifuged three times, five minutes each at 4.4 krcf, replacing the
supernatant with new ethanol each time. Finally the MSN as dry as possible were left to
continue drying in a vacuum chamber overnight.
PEI-coated MSN preparation: Xia and collaborators (2018) described the
methodology that was used with some modification. First, 5 mg of dry MSN with 7.5
mg of PEI were both suspended and vortexed in 1 mL of pure ethanol. The solution in a
falcon 12 mL tube was sonicated for 40 minutes, with periodic times of vortex shaking
every five minutes. Then the PEI-MSN were centrifuged 10 minutes at 4.4 krcf, the
supernatant was discarded by tilting over the tube into the waste vessel. The pellet was
then left to dry in a vacuum chamber.
MSN glucose loading and capping: First, 1 mL of glucose (1 M) was made
in PGM buffer, and then 10 mg of PEI-MSN were resuspended in the glucose solution,
by sonication and vortex. The suspension was then left shaking overnight at room
temperature. Finally, the glucose loaded PEI-MSN, were capped by using 1 mL of Au22

Ab added to the silica solution. The mixture was left to attract each other overnight by
shaking them over the counter in an ice bath. Finally, the resulting composite was
centrifuged for 5 minutes, at 4.4 krcf and the supernatant with free glucose was
discarded, and the nanoparticle composite was resuspended in 500 µL of PGM buffer.
Nanoparticles characterization: MSN, PEI coated MSN, AuNP, and Ab coated
AuNP were all characterized using techniques to determine their electric potential, size,
and shape.
Differential light scattering (DLS): This was performed in a Zetasizer
Nano Range, of Malvern Panalytical. Each sample was diluted to 1:100, in water before
characterization. Plastic 1 mL UV compatible cuvettes were used. Every sample was
read in three trials, which were calculated based on 15 runs. The average intensity was
plotted against the size of the nanoparticles. Then, the curve was fitted with a Gaussian
bell to find the best approximation to the real average size of the nanoparticles.
Zeta potential determination: It was also performed in a Zetasizer Nano
Range, but this time using the appropriate cuvette with gold electrodes to determine the
different charges of the nanoparticles. As with DLS, the nanoparticles were diluted
1:100 before being analyzed.
Transmission electron microscopy (TEM): Finalized samples with coating
were observed under a microscope JEOL 1400 operating at 60 keV. The micrographs
were used to determine the physical dimensions as well as the morphology of MSN and
AuNP.
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Glucose loaded, gold capped, MSN immunoassay: As described by Tang, and
collaborators (2014), after the nanoparticle composite (glucose loaded PEI-MSN /AuAb) is ready, 25 µL per sample of the composite were poured in a clean tube. Then 25
µL of sample is used to start the molecular recognition of the antibody with antigen.
The sample/composite mix is allowed to mix for 20 minutes, with vortex intervals
every five minutes. Finally, the amount of glucose released was measured using a PGM.
The positive control consisted in a sample without analyte that was sonicated to break
the electric attraction between both nanoparticles and release all the glucose.
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CHAPTER THREE:
RESULTS
Invertase Mediated Strategy
PDDA-Au-IO-Ab nanoparticles synthesis: Once the polymer and the gold were
mixed and heated together, the transparent solution (Figure 1A) started to shift its color
to pink after a few minutes (Figure 1B), until it reached a light red color after 30 minutes
of the reaction (Figure 1C). During some attempts, the red color becomes too dark as a
consequence of over evaporation of the water, leaving the nanoparticles more
concentrated. In such cases, the experiment was repeated to rule out any unwanted
effect on the nanoparticles. The PDDA-AuNP were stored at 4 °C and used within the
next five to ten days with the intention of using them as “fresh” as possible.
During the later steps, the red color of the PDDA-AuNP became overwhelmed
by the dark iron oxide nanoparticles. The presence of ferrite was proven by simply
using a magnet to attract it down the microcentrifuge tubes. Even after 40 minutes of
the PDDA-Au-IONP being over a magnet, the supernatant still contained some particles
– as its brown color suggested. Finally, after the addition of the antibody and the final
blocking solution with BSA, some nanoparticles were difficult to resuspend, and some
even became a strong aggregate which was not used for further processes. A schematic
representation of the synthesis process is presented in Figure 2A.
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Figure 1. Visual characterization of PDDA-AuNP synthesis. A) Time zero of the
reaction. B) Change of color after a few minutes. C) The reaction is finished after it
reaches a light red wine color.
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Figure 2. Scheme of synthesis and functioning of invertase-mediated immunoassay
for biodetection. A) PDDA-AuNP synthesis. First the gold and PDDA are mixed
together to form colloids. Then the iron oxide is embedded in the polymer matrix to
generate magnetically responsive nanoparticles. Finally, the antibodies for the analyte
of interest coat the surface of the nanoparticles. B) A sample with analyte is added to a
tube with the PDDA-Au-IO-AbNP. The antibodies in the nanoparticle will recognize
the analyte. After, the invertase-analyte conjugate is added to work as a competitor for
the same antibodies. Lastly, the glucose produced from sucrose, and measured with the
PGM, will be directly proportional to the invertase caught by the antibodies; hence,
inversely proportional to the analyte concentration.
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Figure 3. Different approaches to achieve analyte-invertase conjugation. A) Shaking a
solution of the analyte plus invertase for four hours would attract them together if, for
example, there are opposite electrical charges on the two molecules. This method
worked neither for tacrolimus nor creatinine. B) EDC-NHS mediated conjugation
considering the free carboxylic groups of invertase and the free amine of creatinine.
Creatinine´s amine is in constant resonance at any pH below 11, as a result this attempt
failed. C) EDC-NHS mediated conjugation considering the free carboxylic groups of
synthetized creatinine-derived butanoic acid and the free amine groups of invertase.
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Invertase conjugation methods: Three conjugation approaches were
performed in order to achieve an adequate binding between the analyte (creatinine or
tacrolimus) and invertase (Figure 3). After the first approach failed (Figure 3A),
creatinine was chosen to be used with the other experiments since the molecule has an
amine. The second approach to conjugate creatinine with invertase was performed
using EDC, a common cross-linker in biological applications. EDC reacts with an
exposed carboxylic group (from the invertase in this case) and forms an unstable
acylisourea intermediate that is highly reactive with free amines in another molecule
(Figure 3B). The reactions with EDC were carried out under an Argon atmosphere, to
prevent altercates with the oxygen in air (Figure 4). Unfortunately, the second
conjugation approach did not work. To determine the reasons why the crosslinking did
not happen, a TNBS assay was conducted. It showed that the content of free amines in a
solution of 90 mg/mL of creatinine (the maximum possible to dissolve in water) was
insignificant compared with the calibration curve of lysine, an amino acid with two free
amines per molecule (Figure 5). However, the content of free amines in invertase
molecules was high (Figure 5). That information drove the attention to 2-imino-3methyl-5-oxo-1-imidazolidinyl butyric acid or creatinine butyric acid, a carboxylic acid
which could also be conjugated to invertase using EDC-NHS (Figure 3C).
2-imino-3-methyl-5-oxo-1-imidazolidinyl butyric acid or creatinine butyric
acid synthesis: The complete dissolution of the crystals in DMF after adding 4bromobutyric aid ethyl ester occurred six hours after the start of the reaction.
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Figure 4. Setup to conduct EDC-NHS chemical reactions in an oxygen-free
atmosphere. A) Schematic showing the ports of the chamber. Argon entered through
the inlet port 15 minutes before any reaction and displaced all the oxygen out of the
flask. The air outlet port also worked as an entrance for the reactants; it was taken out to
close the system after the 15 min incubation or when no longer necessary. B) Picture of
the flask containing the reaction stirring. C) Picture of the setup with the outlet needle
attached.
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Figure 5. Normalized absorbance intensity of molecules with free amines in different
concentrations. Black dots and lines represent the calibration curve made with L-lysine.
Blue dots represent the invertase in two different concentrations with high levels of free
amines. The green dot is creatinine, which even at the highest concentration possible,
had a weak absorbance intensity. The red lines represent the standard deviation in each
data point.
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Figure 6. Visual characterization of creatinine butyric acid synthesis. A) Creatinine
upon DMF heating. B) The reaction starts with the addition of 4-bromobutyric aid ethyl
ester. C) Here two views of the same sample are shown to demonstrate that the crystals
are completely dissolved in DMF. D) Precipitation of the new compound in ethyl
acetate. E) Crystals of 2-imino-3-methyl-5-oxo-1-imidazolidinyl butyric acid ethyl ester
hydrobromide. F) Neutralization of the HB in methanol. G) 2-imino-3-methyl-5-oxo-1imidazolidinyl butyric acid ethyl ester in ethanol. H) Final oily product after bringing
pH down.
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It was evident that the crystals were soluble because the reaction went from transparent
with conspicuous crystals inside, to cloudy orange, and finally to translucent, dark
orange (Figure 6A, 6B and 6C, respectively). Once the ethyl acetate was added to the
solution, it became bright orange (Figure 6D). At this point, the new crystals present in
the solution were 2-imino-3-methyl-5-oxo-1-imidazolidinyl butyric acid ethyl ester
hydrobromide (Figure 7B). Those crystals filtered, yielded a yellow powder (Figure 6E).
After neutralization in methanol (Figure 6F), and filtration of the bromide salt, the
ethanol soluble compound was 2-imino-3-methyl-5-oxo-1-imidazolidinyl butyric acid
ethyl ester (Figure 6G, Figure 7C). That compound was hydrolyzed in NaOH, and
finally, the 2-imino-3-methyl-5-oxo-1-imidazolidinyl butyric acid (Figure 7D) was
obtained after reducing the pH to three, evaporation of some of the solvent, and
obtaining an oily solution (Figure 6H).
Thin layer chromatography: Figure 8 shows the result of the TLC.
All the plaques that had the sample (creatinine butyric acid), show a mobile compound
that is not in the creatinine control. Such compound is more soluble in methanol than
chloroform.
Competitive immunoassay: The different immunoassays conducted did not
exhibit production of glucose in any sample, or control. However, when the solutions
with the “invertase conjugate” were tested with sucrose, a positive result of glucose
production was detected by the PGM. Since the PGM does not give a number when the
glucose concentration is too low, but instead it prompts an error, it was not possible to
plot graphs with the information.
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Figure 7. Molecules within the steps on the creatinine butyric acid synthesis.
A) Creatinine tautomer showing a molecule with an imine (pH < 11) or amine (pH >
11). B) 2-imino-3-methyl-5-oxo-1-imidazolidinyl butyric acid ethyl ester hydrobromide.
C) 2-imino-3-methyl-5-oxo-1-imidazolidinyl butyric acid ethyl ester. D) 2-imino-3methyl-5-oxo-1-imidazolidinyl butyric acid or creatinine butyric acid.

34

Figure 8. Thin Layer Chromatography for creatinine vs creatinine butyric acid.
Original creatinine was run in the far left plaque. All the other plaques are examples of
the same product (creatinine butyric acid) in different ratios of mobile face. All the
chloroform to methanol ratios are labeled on top of each plaque. Note that the product
is a compound more soluble in methanol and it is not only creatinine. The TLC was
revealed in an iodine chamber, the picture was brought to gray scale to improve
visibility of the sample moving.
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Figure 9. Particle distribution size and average size of AuNP.
A) DLS of AuNP before antibody coating. B) DLS of AuNP-Ab. C) Particle size
distribution from images obtained in TEM. All the graphs show the average size and
standard deviation.
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Mesoporous Silica Nanoparticles Mediated Strategy:
AuNP-Ab synthesis: Similarly to the PDDA-Au synthesis, the solution changed
color to the same light red wine. Before antibody coating DLS showed the average
particle size to be 6 ± 0.9 nm (Figure 9A). After the coating, the particle size incremented
to 9.12 ± 1.44 nm (Figure 9B); however, under TEM the nanoparticles size distribution
was 16.2 ± 0.6 nm (Figure 9C). TEM images show mostly spherical particles with some
other shapes in much less prevalence. There was some aggregation of particles under
the microscope (Figure 10). Z potential changed from positive (12.3 ± 12 nm) to negative
(-20 ± 5.15 nm), a difference statistically significant when an unpaired t-test was
conducted (Figure 11).
PEI coated Mesoporous Silica Nanoparticles synthesis: DLS of the MSN before
coating showed average size as 198 ± 25 nm, while after coating the size increased to
221.7 (±36.88) nm. Nevertheless, the calculation using TEM images point to 78.4 ± 8.6
nm as the average particle size (Figure 12). Z potential changed from negative (-31.6 ±
5.07 nm) to positive (26.5 ± 3.52 nm) as expected with presence of PEI coating. The Z
potential difference is statistically significant when an unpaired t-test was performed
(Figure 11). Porosity in the MSN can be confirmed thanks to TEM images (Figure 13).
The particles are spherical to some point, but there are more ellipsoidal ones as well.
Some particles appeared to be agglomerated after synthesis.
Glucose loaded, gold capped, MSN immunoassay: The different immunoassays
conducted did not show release of glucose in any sample, or control. Since the PGM
cannot detect very small glucose concentrations, prompting an error, it was no
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Figure 10. TEM pictures of AuNP. The scale bars are 50 nm left, and 20 nm right.
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Figure 11. Average Z potential of nanoparticles involved in the MSN mediated
strategy for bioanalyte detection. Thin, black bars represent the standard deviation.
The p values between before and after coating for each pair of nanoparticles was
obtained with an un-paired t-test calculator.
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Figure 12. Particle distribution size and average size of MSN.
A) DLS of MSN before PEI coating. B) DLS of PEI-MSN. C) Particle size distribution
from images obtained in TEM. All the graphs show the average size and standard
deviation.
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Figure 13. TEM pictures of MSN. The scale bars are 50 nm left, and 10 nm right.
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Figure 14. Scheme of mechanism of MSN-mediated immunoassay for biodetection.
The method involves two nanoparticles and the analyte of internets (top). AuNP-Ab
work as a cap to keep the glucose inside the pores of the PEI-MSN until the electrical
interaction between the particles is interrupted by the presence of the right analyte
(bottom). The glucose released from the MSN, and measured with the PGM, would be
directly proportional to the analyte concentration.
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Figure 15. TEM pictures of MSN and AuNP-Ab. Notice there are too few AuNP-Ab
(more electron dense, pointed by the arrow), per MSN.
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possible to plot graphs with the information. Figure 14 shows a schematic
representation of the technique.
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CHAPTER FOUR:
DISCUSSION
Invertase Mediated Strategy
Invertase has been widely use in POC testing techniques 23-26,63, this is why at
first it looked like a feasible way to create a new mechanism to detect molecules using
the PGM. In order to do so, many teams have used invertase as part of a secondary
piece of the strategy 16,64. This secondary piece can either be an invertase-functionalized
target molecule, or a secondary antibody conjugated to invertase. When working with
secondary antibodies, the idea is to capture a molecule within two antibodies as a
sandwich 35. Although the specificity of sandwich immunoassays is generally better,
realizing one for small molecules, known as haptens, can be challenging 37,65-67. Indeed,
a sandwich immunoassay for the detection of creatinine using a PGM had been
attempted before, with results that point towards using a competitive immunoassay
instead 68. Another molecule of interest, tacrolimus is also considered a hapten, and a
sandwich immunoassays, although possible, is complicated to reproduce 37. Hence, this
project was directed toward developing a competitive immunoassay for detection of
small molecules.
PDDA-Au-IO-Ab nanoparticles: Magnetic nanoparticles were chosen as the
separation method for the immunoassay as has been successful in the past 16,18,68. The
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magnetic beads embedded in a polymer can bring down the polymer in presence of a
magnet, simplifying the washing steps that most immunoassays require. This is an
important factor to consider; especially, since non-technical users are the final targets to
POC testing mechanisms. As the separation moiety, the magnetic nanoparticles should
be able to retain the molecule of interest; this was accomplished by using antibodycoated gold colloids. In theory, PDDA, a cationic polymer, acts as reducing and
stabilizing agent while synthesizing gold nanoparticles from chloroauric acid, forming
stable colloids of gold with narrow size distribution 69. PDDA also can easily bind to
iron oxide functionalized with carboxylic groups 16. These properties made it possible
for both nanoparticles to be held together.
This nanoparticle composite is cost effective and easy to make; most steps can be
followed thanks to the conspicuous characteristics of the solutions (Figure 1). Zhao et al.
(2015) agreed that these characteristics make gold magnetic nanoparticles good
candidates for portable devices. The characterization of these particles under TEM was
performed previously 68. The average size distribution estimates that the nanocomposite
is 82 ± 12 nm.
Invertase conjugation methods: The PDDA-Au-IO-Ab nanoparticles functioned
as detector of the competitive immunoassay under consideration. However, in order to
detect the presence of the analyte, invertase was needed as a translator and amplifier of
the concentration. For that, invertase should be attached to the analyte per se, in order
to complete the scheme for the assay (Figure 2). To achieve that, different methods were
attempted. At first, it was thought that non-covalent interactions between invertase and
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the analyte to be tested were enough to keep them together (Figure 3A). At pH 7, the Z
potential of invertase is slightly negative 70; however, according to pub chem, neither
creatinine nor tacrolimus have a formal charge in this pH.
Invertase, as a macromolecule, has many exposed chemical groups that can be
targeted for crosslinking, for example amine and carboxylic groups. This feature has
been used before to conjugate invertase to other molecules such as biotin 71. Specifically,
the EDC-NHS mediated crosslinking technique was used, since it has been reported
that invertase activity is not altered by conjugation with its amine groups 9,72. However,
considering that creatinine has an amine (Figure 7A), and invertase contains carboxylic
groups, the first attempt was to conjugate them as shown in Figure 3B. In order to test if
the conjugation occurred, a TNBS assay was run. This is a colorimetric technique that
shows the relative amount of free amines in a solution. It was evident that the amine in
the creatinine was not reacting as it should given the fact that 90 mg/mL of creatinine
were not nearly as orange as 0.195 mg/mL of L-lysine (Figure 5). This result proved that
creatinine in fact has an amide in any neutral solution (Figure 7A), for which the
experiment could not have been successful. Possibly, if the invertase – creatinine
conjugation is conducted on a buffer with pH higher than 11, the amine can be there to
react with the invertase-EDC intermediate. Nonetheless, invertase does not tolerate
high pH values, and it could lose activity. Also, according to manufacturer instructions,
EDC conjugation is recommended to be done at slightly acidic pH values. This explains
why the conjugation process was altered to a third attempt (Figure 3C).
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Modifying the structure of creatinine to generate an exposed chemical group
could make an EDC-NHS mediated linking feasible. This modification had been
performed before with the purposed of creating an ELISA, with an intermediate
molecule having a free carboxylic group 56. This molecule, 2-imino-3-methyl-5-oxo-1imidazolidinyl butyric acid, or creatinine butyric acid, fitted in the scheme of using a
carboxylic acid and link it to a free amine in the invertase (Figure 3C). However, this
particular molecule was not available for purchase, so chemical synthesis was the way
to go. The process as described in chapter 2 and illustrated in Figure 6, was performed
and the final product appeared to be different from the original creatinine (Figure 8).
However, further characterization of the final compound by means of NMR was not
carried out.
Competitive immunoassay: Unfortunately, none of the attempts to carry out an
immunoassay worked appropriately. Every time the glucose was measured with the
PGM an error message was reported. The error interpretation according to the PGM’s
manufacturer instructions implied that the solution did not have enough glucose for the
device to detect. There were some pitfalls where the experiments could have failed. The
most evident one is the lack of check points, especially after chemical synthesis. In
other words, after the conjugation trials represented in Figure 3, a nuclear magnetic
resonance characterization could have been carried out to confirm whether conjugation
of the molecules.
Another issue may have been the antibodies’ activity. Although it has been
published that some antibodies lifespan can be up to 14 years when stored at 4 °C,
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others can last only a couple weeks 73. The antibodies used in this project were always
stored at -20 °C as recommended by the seller; however thawing-freezing cycles may
have harmed them. Furthermore, antibodies recommended for conjugation purposes
are usually sold in PBS without any preserving agent that may interfere in the reactions
73.

Antibodies used during the project came diluted in a buffer containing sodium aside,

EDTA and probably protease inhibitors. Since TEM cannot determine whether or not
the antibodies are present, it is possible that these never AuNP.
One lingering question from the immunoassay experiments was, what is the best
way to proceed with washing steps? Theoretically these steps wash away any nonbound molecule from the media, keeping only what is recognized by the antibodies,
hence attracted to the magnet. Yet, it was noticed that the addition of fresh solution to
the wells with the pipette, physically moved the visible magnetic nanoparticles at the
bottom of the well. Such force could have potentially removed any bound material
simply by pushing it away, which would have translated in any invertase retained and
no glucose generated.
It is worthy to note that unlike invertase, neither tacrolimus nor creatinine are
molecules “ready” or easy to conjugate. To the best knowledge of the author, creatinine
has only been conjugated after modification of its chemical structure to creatinine
butyric acid 56. On the other hand, tacrolimus has been conjugated to different
molecules, such as BSA, HRP, dextran, etc. 38,62,74. Particularly, it has been conjugated
with the purpose of generating antibodies for it 37. Yet, it is still a molecule difficult to
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handle because it exhibits poor solubility in water-based solutions, where invertase can
be handled 37,62.
Considering that after three different trials, the immuno-detection was not
possible, the strategy for detection of molecules was changed to an approach with less
variables, less synthesis procedures, no washing steps and less time to get a result. That
alternative strategy was the glucose-loaded MSN strategy.
Summary: Detection of creatinine and tacrolimus through a competitive
immunoassay was attempted. The technique involves two pieces, a receptor-separator
magnetic nanocomplex and a transductor-amplifier nanocomplex with invertase. The
NPs’ morphology was as expected, however antibody conjugation was not apparent.
The signal revealing molecule was invertase conjugated to the target hapten in order to
induce competition in the immunoassay. Three approaches to proceed with such
conjugation, represented in Figure 3, were conducted but all of them failed. The first
one, based on non-covalent conjugation was likely not possible because of the null
charges of creatinine and tacrolimus under experimental conditions. The second
approach relied on a free imine in creatinine’s molecular structure. Instead of that,
creatinine has an imide group in neutral pH, that group did not allow the EDC-NHS
mediated conjugation. Finally, the last attempt gave some hope since it was evident that
a new compound was produced at the end on the TLC plates. However, NMR analysis
was not performed to confirm the modification of the molecule and the conjugation to
an enzyme. Regardless, immunoassay with this product was unsuccessful. The main
pitfalls identified were the antibodies instability, the difficult nature of the target
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molecules, and non-uniform, sample disruptive, washing steps. As a result, the focus of
the project shifted to a method with less steps/variables.
Mesoporous Silica Nanoparticles Mediated Strategy:
Detection of glucose can be achieved in other ways besides using invertase as an
intermediate. One of the ways is to contain the glucose trapped in the media from the
beginning. Then, such trapping should respond to the presence of the analyte. That is
how the glucose-loaded MSN strategy works (Figure14). The method avoids any
chemical conjugations, besides gold and antibody. It does not require washing steps,
and the overall time from “sample dropping” to obtaining the results is only 30
minutes, probably less 75.
AuNP-Ab synthesis: The AuNPs were synthesized in a single step. The
Turkevich method to prepare gold colloids has been used frequently in diverse
applications that require homogenous particle size distribution 75,76. Similar to the
PDDA-AuNPs from the previous strategy, these nanoparticles changed color and could
be characterized to some extent during the synthesis process. Further analysis of the
particles showed a size distribution around 6 nm under DLS, and 9 nm after antibody
coating (Figure 9). At the same time, TEM size distribution of the same particle put
them in 16 nm of diameter for the most of them. This size discrepancy may be a
consequence of polydispersion of the nanoparticles, which is not well tolerated by DLS
77.

There is a common belief that DLS is not as accurate as TEM, since the last one

actually allows seeing the NP, indeed, DLS measurement fluctuate greatly when the
dispersion of the sample is not ideal 77,78. Furthermore, DLS estimation of sizes has been
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reported up to five times bigger than their TEM counterparts, especially in samples
with mixed different sizes 77. However, the size distribution comes from the images
taken, which in many times is not an accurate representation of the whole population.
Antibody conjugation in this case was confirmed with z potential measure. AuNP
before the conjugation were charged positively, and after it, the z potential of the
particles were negative (Figure 11).
PEI coated Mesoporous Silica Nanoparticles synthesis: MSN synthesis was
problematic to begin with since minimal variation between the ratios of CTAB, TEOS
and water, can change the size of the nanoparticles, as well as the shape of them 79-81.
Apparently, even the way of adding the TEOS (dropwise vs injection) to the stirring
CTAB solution is important and can have an effect on the NPs 79,80. Another important
aspect of the synthesis was the filtration steps. After trying different methods that
included filtration processes, it was not until after replacing the filtration for
centrifugation 79 that the MSN obtained were small enough to keep in suspension for at
least a few minutes. Otherwise, the MSNs were insoluble. PEI coating was surprisingly
easy to perform and effective. The particle size distribution went from 198 nm before
the PEI to 221 nm after it. Additionally, the polymer coat facilitate their dispersal in
solvent. Nonetheless, TEM estimated average size only reached 78 nm, showing again a
discrepancy between the techniques. Usually particles in suspension are covered in a
“water-shell” that can be analyzed by the DSL characterization as part of the particle
size. The presence of PEI coating was confirmed by the zeta potential of the MSN.
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Before polymer coating, the MSNs were slightly negative, but after, the desired PEI
positive charge was evident (Figure 11).
Glucose loaded, gold capped, MSN immunoassay: The immunoassay
conducted did not give positive results. The number one reason for this is that a AuNPAb to MSN ratio was not optimized. TEM images (Figure 15) of the whole
nanocomposite show the discrepancy between the ratios. There were not enough gold
nanoparticles to effectively cap entire MSN nanoparticles and actually work as a cap for
the glucose (Figure 15); in other words, the glucose was never trapped inside MSN
porous. Possibly, after tuning such procedure, an immunoassay can be successfully
carried out.
A secondary possibility is that MSN’s pores were not big enough to hold
substantial amounts of glucose that could actually be measured by the PGM. Similarly,
MSN size could also be a problem in that 70 nm is perhaps not optimal to carry an
adequate amount of glucose. At best, both AuNP-Ab and MSN looked, and behaved as
they should according to the characterization protocol.
Summary: A single step immunoassay as illustrated in Figure 14 was developed.
The first piece of the strategy, AuNP-Ab were prepared using the Turkovitch method,
and then coating with Ab overnight. The size distribution showed particles fluctuating
around 10 nm in diameter. The antibody conjugation was successfully confirmed by the
change in zeta potential of the NP before and after coating. As expected, the final charge
of the AuNP was negative. On the other hand, the second half of the strategy were
MSNs, prepared using TEOS as the precursor of silica, and formed in a surfactant
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solution (CTAB) to create the pores. Average particle size of these NPs was around 80
nm according to TEM analysis. Coating with PEI was carried out to make the surface of
the nanoparticles positive. That was confirmed by their zeta potential after the PEI
coating. The electrostatic interaction between both PEI-MSNs and AuNP-Ab was
intended to keep the glucose inside the MSN pores, until the presence of an analyte
disturbed such state. However, the ratio between AuNP-Ab and PEI-MSN did not
effectively cap the glucose within the MSN to begin with (Figure 15). A higher
concentration of gold, or lower MSN concentration, should be used in future analyses.
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CHAPTER FIVE:
CONCLUSIONS AND FUTURE PROSPECTS
Two different nanoparticle-assisted techniques for the detection of small
molecules were explored. First, an invertase-mediated technique using magnetic
nanoparticles as the separation moiety was presented. To do so, invertase had to be
conjugated with the analyte of interest so it could work as a competitor for the original
analyte in the sample. Three conjugation approaches were pursued but unfortunately
none of them (Figure 3). The last approach, where creatinine butyric acid was
synthetized from creatinine has the potential to work in the future. However,
characterization of the synthetized molecule through NMR should be conducted.
Besides the possible failure of invertase-creatinine conjugation, other reasons for which
the assay may have failed are, bad condition of the antibodies, and damaging of the
composite in washing steps.
A different technique with reduced complexity, as well as one step approach was
also tried. For this, two nanoparticle moieties with opposite charges were created. One
of them was AuNP-Ab that worked as a cap for the second moiety, glucose-loaded
mesoporous silica nanoparticles (Figure 14). Both nanoparticles were prepared and
characterized by way of DLS, TEM and zeta potential. Although they looked and
behaved as expected, the immunoassay trials did not work. The most probable reason is
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an incorrect ratio between MSN and AuNP-Ab (Figure 15); where the latter was not
enough to completely surround each MSN, leading to glucose leakage before the assay.
Overall, the invertase-independent technique offers better features for the design
of a biodiagnostic tool. Future optimization of MSN:AuNP-Ab will be required to move
forward with the development of the technique. Alternatively, use of antibody could be
substituted with a MIP in the future. This approach will avoid the inherent drawbacks
of using antibodies, such as activity lost due to denaturation, after changes in the pH,
salinity, heat, and other factors 82. Furthermore, antibodies show clone-to-clone
variability, they tend to be the most expensive reactive in POC assays and they are
required to be refrigerated at all times 83.
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